Vistagen Therapeutics is a late clinical-stage biopharmaceutical company engaging in the treatment for individuals living with anxiety, depression and other central nervous system disorders. Co.'s product candidates include: fasedienol (PH94B), which is used for treatment of social anxiety disorder; Itruvone (PH10), which is used for depression disorders; PH80, which is used for treatment of both vasomotor symptoms (hot flashes) due to menopause and migraine headaches; PH15, which is used for treatment to improve cognitive impairment caused by mental fatigue and other disorders; and AV-101, which is an oral prodrug that targets the N-methyl-D-aspartate receptor. We show 37 historical shares outstanding datapoints in our VTGN shares outstanding history coverage, used to compute VTGN market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing VTGN market cap history over the course of time is important for investors
interested in comparing VTGN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of VTGN versus a peer is one thing; comparing
VTGN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like VTGN can fluctuate over the course of history.
With this page we aim to empower investors researching VTGN by allowing them to research the VTGN market cap history. |
Free VTGN Email Alerts:
Video: The Importance of Market Cap
